Citation

Wiser I, Balicer RD, Cohen D. Vaccine 2007; 25(6): 976-984.

Affiliation

Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel. wiser@post.tau.ac.il

Copyright

(Copyright © 2007, Elsevier Publishing)

DOI

10.1016/j.vaccine.2006.09.046

PMID

17074424

Abstract

The threat of using variola virus in a bioterrorist attack urged different countries to renew the production of traditional vaccines and develop new generations of smallpox vaccines. Manufacturers try to combine smallpox vaccine past experience with technological advances in vaccine development to achieve protection similar to that of the traditional vaccines with a higher level of safety and fewer contraindications. In light of the reported immunogenicity and reactogenicity of the stockpiled smallpox vaccines employed in the last immunization campaigns of "first responders", we review recently accumulated data on the assessment of new smallpox vaccine candidates and discuss their role in possible vaccination policies.

Language: en